Warren Peters, MD, MPH, FOMA
Director – Metabolic Obesity Research Clinic (MORC)
Associate Professor
LOMA LINDA UNIVERSITY – School of Public Health
From Dopamine Pills to Personalized Neurons: Aspen’s Autologous Cell Therapy for Parkinson’s Disease
Parkinson’s disease (PD) has long been managed through pharmacology: levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and complex delivery systems designed to keep dopamine levels within a workable range. These treatments have transformed daily life for many people, but they all share a limitation—they do not replace the neurons that have died.
By the time PD is clinically diagnosed, a substantial fraction of dopamine-producing neurons in the substantia nigra and their projections to the putamen have already been lost. This loss underlies many of the motor features of PD and likely interacts with non-motor symptoms through broader network changes. To date, there is no approved therapy that clearly restores these neurons or stops their progressive loss.
Why Cell Replacement?
The logic of cell replacement for Parkinson’s is straightforward: if loss of dopaminergic neurons is central to the disease, perhaps we can rebuild that circuitry by adding new cells. Attempts along these lines are not new. Fetal mesencephalic tissue transplants were explored decades ago, and more recently, allogeneic stem cell–derived dopaminergic cell lines have moved into early clinical studies. These approaches face challenges related to tissue sourcing, variability, immune rejection, and ethical considerations.
Aspen Neuroscience is pursuing a different angle: autologous, iPSC-derived neuron replacement. Rather than using donor tissue or a “universal” cell line, their approach starts with each patient’s own cells and ends with a bespoke cell therapy designed for that individual.
Inside ANPD001: An Autologous iPSC-Derived Therapy
ANPD001, Aspen’s lead investigational product, is built on a three-step manufacturing process:
- Skin biopsy and iPSC generation. A small sample of the patient’s skin cells is collected. These cells are reprogrammed into induced pluripotent stem cells (iPSCs), which can, in principle, become many cell types.
- Differentiation into dopaminergic neuron precursors. Using defined culture conditions and developmental cues, the iPSCs are directed to become dopaminergic neuron precursor cells (often called DANPCs). These cells are intended to resemble the midbrain dopaminergic neurons lost in PD.
- Quality control and release testing. At each stage, cells undergo extensive phenotypic, functional, and genomic quality assessment. Aspen emphasizes the use of machine learning–based genomic tools to detect genetic or epigenetic abnormalities that might affect safety or function. Only products meeting predefined criteria move forward to transplantation.
The resulting DANPCs are then transplanted into the putamen, a key striatal region involved in motor control. The rationale is to place new, dopamine-capable cells at the site where dopaminergic input has been lost, rather than upstream in the midbrain. If successful, these cells should integrate, extend processes, release dopamine, and respond to physiological signals in ways that support motor function.
The ASPIRO Trial: Testing ANPD001 in People with PD
To evaluate ANPD001 in humans, Aspen is conducting ASPIRO, a Phase 1/2a, open-label, dose-escalation trial in people with moderate to severe Parkinson’s disease whose symptoms are no longer adequately controlled by standard oral therapies. As with most early-phase trials, the primary endpoint is safety and tolerability—both of the cell product and of the neurosurgical delivery procedure.
Secondary endpoints include:
- Changes in “on” time (periods when medication provides good symptom control)
- Motor outcomes based on standard PD rating scales
- Quality-of-life measures reported by patients and clinicians
Notably, ANPD001 has received Fast Track designation from the U.S. Food and Drug Administration (FDA). Fast Track is intended to speed development and review of therapies for serious conditions that address unmet medical needs. It provides more frequent interactions with the FDA and potential eligibility for accelerated approval pathways if the data support it. Fast Track does not imply that a therapy is proven to work, but it does signal regulatory recognition of the program’s potential importance.
Autologous vs. Allogeneic: Why Use the Patient’s Own Cells?
Many cell therapy programs explore allogeneic (“off-the-shelf”) products derived from donor cells. Autologous products like ANPD001 are more complex to manufacture, but they may offer specific advantages:
- Reduced immune rejection: Because the cells originate from the patient, the risk of immune-mediated rejection may be lower, potentially reducing the need for chronic immunosuppression.
- Patient-specific biology: Autologous products can, in theory, account for individual genomic background, although this also raises questions about whether disease-related vulnerabilities might be carried into the new cells.
- Personalization: Each batch is built for one person, aligning with broader trends toward individualized medicine.
These potential advantages must be weighed against challenges, including manufacturing complexity, time to produce each batch, cost of goods, and logistical coordination between biopsy, production, and transplantation.
Safety, Unknowns, and the Long View
Cell therapies that involve neurosurgical delivery raise several important safety considerations: surgical risk, risk of graft overgrowth or tumor formation, ectopic cell differentiation, immune responses, and long-term stability of the graft. Aspen’s extensive quality control and genomic surveillance pipeline is designed to mitigate some of these concerns, but only time and data will clarify the actual risk profile.
On the efficacy side, key questions include:
- How many cells are needed to achieve meaningful motor benefit?
- Will benefits, if observed, plateau, grow, or diminish over time?
- How early or late in disease course should such interventions be considered?
- Will cell replacement affect non-motor symptoms, or primarily motor function?
Because ASPIRO is an early-phase study, it is not designed to answer all of these questions definitively. However, it can provide foundational insights into feasibility, initial safety, and possible clinical signals that justify larger, controlled studies.
What It Means for People with Parkinson’s Today
For individuals and families living with Parkinson’s, it is essential to recognize that ANPD001 is an investigational therapy available only through clinical trials. Aspen does not currently offer compassionate use or expanded access programs for ANPD001, and there is no approved cell replacement therapy for PD at this time.
That said, efforts like Aspen’s mark an important shift in the field: from purely symptomatic management toward attempts at structural repair and circuit restoration. Even if ANPD001 itself ultimately needs refinement or is complemented by other approaches, the work contributes to a growing body of knowledge about how to safely manufacture, monitor, and deliver cell-based therapies for neurodegenerative diseases.
In future BrainSignals episodes, we will continue to follow cell replacement efforts, including autologous and allogeneic strategies, as well as other disease-modifying approaches. The goal is not to promote any specific product, but to help patients, families, and clinicians track where the science is heading—and to distinguish realistic promise from premature hype.
For now, the message is cautious optimism: cell replacement is no longer just a concept on a whiteboard. It is being tested in real people with Parkinson’s disease, under careful clinical supervision, with an eye toward a future in which replacing lost neurons might become part of standard care.
________________________________________